ムスカリン受容体刺激薬、ムスカリン作動薬、ムスカリン作用薬、ムスカリンアゴニスト

関: muscarinic、muscarinic cholinergic agonist、muscarinic receptor agonist

WordNet

(biochemistry) a drug that can combine with a receptor on a cell to produce a physiological reaction
a muscle that contracts while another relaxes; "when bending the elbow the biceps are the agonist"
someone involved in a contest or battle (as in an agon)

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2014/04/30 22:56:12」(JST)

wiki en

Muscarine

A muscarinic receptor agonist is an agent that activates the activity of the muscarinic acetylcholine receptor. The muscarinic receptor has different subtypes, labelled M1-M5, allowing for further differentiation.

Clinical significance

M1

M1-type muscarinic acetylcholine receptors play a role in cognitive processing. In Alzheimer disease (AD), amyloid formation may decrease the ability of these receptors to transmit signals, leading to decreased cholinergic activity. As these receptors themselves appear relatively unchanged in the disease process, they have become a potential therapeutic target when trying to improve cognitive function in patients with AD.^[1]^[2]^[3]

A number of muscarinic agonists have been developed and are under investigation to treat AD. These agents show promise as they are neurotrophic, decrease amyloid depositions, and improve damage due to oxidative stress. Tau-phosphorylation is decreased and cholinergic function enhanced. Notably several agents of the AF series of muscarinic agonists have become the focus of such research:. AF102B, AF150(S), AF267B. In animal models that are mimicking the damage of AD, these agents appear promising.

The agent xanomeline has been proposed as a potential treatment for schizophrenia.^[4]^[5]

M3

In the form of pilocarpine, muscarinic receptor agonists have been used medically for a short time.

M3 agonists
- Aceclidine, for glaucoma.
- Arecoline, an alkaloid present in the Betel nut.
- Pilocarpine is a drug that acts as a muscarinic receptor agonist that is used to treat glaucoma.
- Cevimeline (AF102B) (Evoxac) is a muscarinic agonist that is an Food and Drug Administration (FDA)-approved drug and used for the management of dry mouth in Sjögren's syndrome.

Muscarinic versus nicotinic activity

Comparison of cholinergic agonists ^[6]
Substance	Receptor specificity		Hydrolysis by acetylcholinesterase	Comments
Substance	Muscarinic	Nicotinic	Hydrolysis by acetylcholinesterase	Comments
Choline	+++	+++	++	Essential nutrient
Acetylcholine	+++	+++	+++	Endogenous ligand
Carbachol	++	+++	-	Used in the treatment of glaucoma
Methacholine	+++	+	++	Used to diagnose bronchial hyperreactivity,^[7] a hallmark of asthma and COPD.
Bethanechol	+++	-	-	Used in bladder and gastrointestinal hypotonia.
Muscarine	+++	-	-	Natural alkaloid found in certain mushrooms. Cause of mushroom poisoning
Nicotine	-	+++	-	Natural alkaloid found in the tobacco plant.
Pilocarpine	++	-	-	Used in glaucoma.
Oxotremorine	++	-	-	Used in research to induce symptoms of Parkinson's disease.

Muscarinic Acetylcholine Receptor Subtypes

The targets for Muscarinic agonists include the following receptors:

Receptor/Transporter Protein
M₁
M₂
M₃
M₄
M₅

References

^ Fisher A, Brandeis R, Bar-Ner RH, Kliger-Spatz M, Natan N, Sonego H, Marcovitch I, Pittel Z. AF150(S) and AF267B: M1 muscarinic agonists as innovative therapies for Alzheimer's disease. J Mol Neurosci. 2002 Aug-Oct;19(1-2):145-53. PMID 12212772
^ Fisher A. M1 muscarinic agonists: Their potential in treatment and as disease-modifying agents in Alzheimer's disease Drug Dev. Res. 50:291-297, 2000. [1]
^ Fisher A (July 2008). "Cholinergic treatments with emphasis on m1 muscarinic agonists as potential disease-modifying agents for Alzheimer's disease". Neurotherapeutics 5 (3): 433–42. doi:10.1016/j.nurt.2008.05.002. PMID 18625455.
^ Shekhar A, Potter WZ, Lightfoot J, et al. (July 2008). "Selective Muscarinic Receptor Agonist Xanomeline as a Novel Treatment Approach for Schizophrenia". Am J Psychiatry 165 (8): 1033–9. doi:10.1176/appi.ajp.2008.06091591. PMID 18593778.
^ Sellin AK, Shad M, Tamminga C. (November 2008). "Muscarinic agonists for the treatment of cognition in schizophrenia". CNS Spectrums 13 (1): 985–96. PMID 19037177.
^ Unless else specified in boxes, then reference is: Table 10-3 in: Rod Flower; Humphrey P. Rang; Maureen M. Dale; Ritter, James M. (2007). Rang & Dale's pharmacology. Edinburgh: Churchill Livingstone. ISBN 0-443-06911-5.
^ Birnbaum S, Barreiro TJ (June 2007). "Methacholine challenge testing: identifying its diagnostic role, testing, coding, and reimbursement". Chest 131 (6): 1932–5. doi:10.1378/chest.06-1385. PMID 17565027.

External links

Muscarinic Agonists at the US National Library of Medicine Medical Subject Headings (MeSH)

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. シェーグレン症候群における口内乾燥およびその他の非眼結膜炎症状の治療 treatment of dry mouth and other non ocular sicca symptoms in sjogrens syndrome
2. 気道の神経制御 neuronal control of the airways
3. 尿失禁の治療 treatment of urinary incontinence
4. 成人における禁煙のための薬物療法 pharmacotherapy for smoking cessation in adults
5. 天疱瘡の病因、臨床症状、および診断 pathogenesis clinical manifestations and diagnosis of pemphigus

English Journal

Scopolamine and amphetamine produce similar decision-making deficits on a rat gambling task via independent pathways.

Silveira MM1, Malcolm E2, Shoaib M2, Winstanley CA3.
Behavioural brain research.Behav Brain Res.2015 Mar 15;281:86-95. doi: 10.1016/j.bbr.2014.12.029. Epub 2014 Dec 18.
Disorders characterized by disturbed cholinergic signaling, such as schizophrenia, exhibit impaired performance on measures of real-world cost/benefit decision-making. Whether the cholinergic system contributes to the choice deficits observed is currently unknown. We therefore determined the effects
PMID 25529186

In vitro recordings of human neocortical oscillations.

Florez CM1, McGinn RJ1, Lukankin V1, Marwa I1, Sugumar S1, Dian J1, Hazrati LN2, Carlen PL3, Zhang L4, Valiante TA5.
Cerebral cortex (New York, N.Y. : 1991).Cereb Cortex.2015 Mar;25(3):578-97. doi: 10.1093/cercor/bht235. Epub 2013 Sep 17.
Electrophysiological oscillations are thought to create temporal windows of communication between brain regions. We show here that human cortical slices maintained in vitro can generate oscillations similar to those observed in vivo. We have characterized these oscillations using local field potenti
PMID 24046077

Solabegron : a potential future addition to the β-3 adrenoceptor agonist armamentarium for the management of overactive bladder.

Ellsworth P1, Fantasia J.
Expert opinion on investigational drugs.Expert Opin Investig Drugs.2015 Mar;24(3):413-419. Epub 2015 Jan 5.
Introduction: Overactive bladder (OAB) affects many women and men worldwide and has a significant adverse effect on a person's quality of life. Historically, behavioral therapy and anti-muscarinic agents have been the primary therapies used in the management of OAB. However, persistence with anti-mu
PMID 25557359

Japanese Journal

Selective M_3 Muscarinic Receptor Antagonist Inhibits Small-Cell Lung Carcinoma Growth in a Mouse Orthotopic Xenograft Model

AMI Nozomi,KOGA Kazumi,FUSHIKI Hiroshi,UENO Yoko,OGINO Yoshio,OHTA Hisashi
Journal of pharmacological sciences 116(1), 81-88, 2011-05-20
… In small cell lung carcinoma (SCLC), acetylcholine (ACh) is synthesized and secreted, and it acts as an autocrine growth factor through activation of its receptors, muscarinic receptor (mAChR) and nicotinic receptor (nAChR). … We used a highly selective M3 muscarinic antagonist, N-(2-[3-([3R]-1-(cyclohexylmethyl)-3-piperidinyl]methylamino)-3-oxopropyl]amino-2-oxoethyl)-3,3,3-triphenyl-propioamide (J-115311). …
NAID 10029894058

Decreased Motility of the Lower Esophageal Sphincter in a Rat Model of Gastroesophageal Reflux Disease May Be Mediated by Reductions of Serotonin and Acetylcholine Signaling

Saegusa Yayoi,Takeda Hiroshi,Muto Shuichi,Oridate Nobuhiko,Nakagawa Koji,Sadakane Chiharu,Nahata Miwa,Harada Yumi,Iizuka Mizuki,Hattori Tomohisa,Asaka Masahiro
Biological & Pharmaceutical Bulletin 34(5), 704-711, 2011
… The in vivo motility proximal to LES (% motility index) in conscious rats was decreased by atropine treatment and increased by cisapride (5-HT4 receptor agonist) treatment. … The mRNA expressions of 5-HT4 and muscarinic acetylcholine 3 receptors were significantly reduced in esophageal LES strips of GERD rats compared with sham-operated rats. …
NAID 130000657784

「ムスカリン作用薬」

　　[★]

英: muscarinic agonist、muscarinic
関: ムスカリニック、ムスカリン、ムスカリン性、ムスカリン様、ムスカリン作動薬、コリン作用薬、ムスカリン性薬物、コリン作動薬、ムスカリン受容体刺激薬、ムスカリンアゴニスト

「ムスカリン受容体刺激薬」

　　[★]

英: muscarinic agonist、muscarinic receptor agonist、muscarinic cholinergic agonist
関: ムスカリン作動薬、ムスカリン作用薬、ムスカリンアゴニスト

「ムスカリン作動薬」

　　[★]

英: muscarinic agonist, muscarinic cholinergic agonist
関: ムスカリン作用薬、ムスカリン受容体刺激薬、ムスカリンアゴニスト

「ムスカリンアゴニスト」

　　[★]

英: muscarinic agonist
関: ムスカリン作動薬、ムスカリン作用薬、ムスカリン受容体刺激薬

「muscarinic cholinergic agonist」

　　[★]

ムスカリン受容体刺激薬、ムスカリン作動薬

関: muscarinic agonist、muscarinic receptor agonist

「muscarinic」

　　[★]

adj.

ムスカリン性の、ムスカリンの

n.

ムスカリン作用薬

関: cholinergic、cholinergic agent、cholinergic drug、cholinomimetic、muscarine、muscarinic agent、muscarinic agonist

[1] Fisher A, Brandeis R, Bar-Ner RH, Kliger-Spatz M, Natan N, Sonego H, Marcovitch I, Pittel Z. AF150(S) and AF267B: M1 muscarinic agonists as innovative therapies for Alzheimer's disease. J Mol Neurosci. 2002 Aug-Oct;19(1-2):145-53. PMID 12212772

[2] Fisher A. M1 muscarinic agonists: Their potential in treatment and as disease-modifying agents in Alzheimer's disease Drug Dev. Res. 50:291-297, 2000. [1]

[pmid18625455-3] Fisher A (July 2008). "Cholinergic treatments with emphasis on m1 muscarinic agonists as potential disease-modifying agents for Alzheimer's disease". Neurotherapeutics 5 (3): 433–42. doi:10.1016/j.nurt.2008.05.002. PMID 18625455.

[pmid18593778-4] Shekhar A, Potter WZ, Lightfoot J, et al. (July 2008). "Selective Muscarinic Receptor Agonist Xanomeline as a Novel Treatment Approach for Schizophrenia". Am J Psychiatry 165 (8): 1033–9. doi:10.1176/appi.ajp.2008.06091591. PMID 18593778.

[pmid19037177-5] Sellin AK, Shad M, Tamminga C. (November 2008). "Muscarinic agonists for the treatment of cognition in schizophrenia". CNS Spectrums 13 (1): 985–96. PMID 19037177.

[Rang.26Dale6thUnless-6] Unless else specified in boxes, then reference is: Table 10-3 in: Rod Flower; Humphrey P. Rang; Maureen M. Dale; Ritter, James M. (2007). Rang & Dale's pharmacology. Edinburgh: Churchill Livingstone. ISBN 0-443-06911-5.

[pmid17565027-7] Birnbaum S, Barreiro TJ (June 2007). "Methacholine challenge testing: identifying its diagnostic role, testing, coding, and reimbursement". Chest 131 (6): 1932–5. doi:10.1378/chest.06-1385. PMID 17565027.

リンク元	「ムスカリン作用薬」「ムスカリン受容体刺激薬」「ムスカリン作動薬」「ムスカリンアゴニスト」「muscarinic cholinergic agonist」
関連記事	「muscarinic」

匿名

検索

案内

案内

muscarinic agonist